The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G04 | Urologicals | |
| 3 | G04B | Other urologicals, incl. antispasmodics | |
| 4 | G04BD | Urinary antispasmodics | |
| 5 | G04BD10 | Darifenacin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 7.5 mg |
| Active Ingredient | Description | |
|---|---|---|
| Darifenacin |
Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EMSELEX Prolonged-release tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ENABLEX Extended-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
